Aclaris Therapeutics reports ‘positive’ results from ATI-2138

TIPRANKS01-27

Aclaris Therapeutics (ACRS) announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine mod...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment